JP6964351B2 - 新規ｔ細胞受容体およびそれを用いた免疫療法 - Google Patents

新規ｔ細胞受容体およびそれを用いた免疫療法 Download PDF

Info

Publication number
JP6964351B2
JP6964351B2 JP2019508259A JP2019508259A JP6964351B2 JP 6964351 B2 JP6964351 B2 JP 6964351B2 JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019508259 A JP2019508259 A JP 2019508259A JP 6964351 B2 JP6964351 B2 JP 6964351B2
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
antigen recognition
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528061A (ja
JP2019528061A5 (enExample
Inventor
アルテン，レオニー
マウラー，ドミニク
ウォルター，ステファン
バンク，ゼバスティアン
Original Assignee
イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60419980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6964351(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イマティクス バイオテクノロジーズ ゲーエムベーハー filed Critical イマティクス バイオテクノロジーズ ゲーエムベーハー
Publication of JP2019528061A publication Critical patent/JP2019528061A/ja
Publication of JP2019528061A5 publication Critical patent/JP2019528061A5/ja
Priority to JP2021128303A priority Critical patent/JP2021184729A/ja
Application granted granted Critical
Publication of JP6964351B2 publication Critical patent/JP6964351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2019508259A 2016-08-17 2017-07-04 新規ｔ細胞受容体およびそれを用いた免疫療法 Active JP6964351B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128303A JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
DE102016115246.3 2016-08-17
US62/376,059 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US201662376632P 2016-08-18 2016-08-18
US62/376,632 2016-08-18
PCT/EP2017/066630 WO2018033291A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128303A Division JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Publications (3)

Publication Number Publication Date
JP2019528061A JP2019528061A (ja) 2019-10-10
JP2019528061A5 JP2019528061A5 (enExample) 2020-02-20
JP6964351B2 true JP6964351B2 (ja) 2021-11-10

Family

ID=60419980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508259A Active JP6964351B2 (ja) 2016-08-17 2017-07-04 新規ｔ細胞受容体およびそれを用いた免疫療法
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Country Status (18)

Country Link
US (2) US10550182B2 (enExample)
EP (1) EP3500593B1 (enExample)
JP (2) JP6964351B2 (enExample)
CN (1) CN109563149A (enExample)
AU (2) AU2017312361B2 (enExample)
BR (1) BR112019001922A2 (enExample)
CA (1) CA3031995A1 (enExample)
CR (1) CR20190095A (enExample)
DE (1) DE102016115246C5 (enExample)
DK (1) DK3500593T3 (enExample)
LT (1) LT3500593T (enExample)
MA (1) MA45976B1 (enExample)
MX (1) MX395287B (enExample)
PE (1) PE20190477A1 (enExample)
RS (1) RS62498B1 (enExample)
SG (1) SG11201900955VA (enExample)
TW (1) TWI775768B (enExample)
WO (1) WO2018033291A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
AU2018326805B2 (en) 2017-09-01 2023-11-30 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
IL274505B2 (en) 2017-11-06 2024-04-01 Immatics Biotechnologies Gmbh Novel engineered t cell receptors and immune therapy using the same
CN111684062A (zh) 2018-02-09 2020-09-18 伊玛提克斯美国公司 制造t细胞的方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
MX2020014191A (es) 2018-06-19 2021-03-09 Dsm Ip Assets Bv Variantes de enzimas lipoliticas.
JP7672979B2 (ja) * 2019-01-22 2025-05-08 アメリカ合衆国 Ｇ１２ｒ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
ES2991645T3 (es) 2019-06-06 2024-12-04 Immatics Biotechnologies Gmbh Clasificación con contraselección mediante péptidos de secuencia similar
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN117986350B (zh) * 2023-02-23 2024-08-16 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7820401B2 (en) * 2004-08-23 2010-10-26 Albert Einstein College Of Medicine Of Yeshiva University Collagen VI and cancer
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
WO2016011210A2 (en) * 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
RU2739500C2 (ru) * 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях

Also Published As

Publication number Publication date
JP2019528061A (ja) 2019-10-10
JP2021184729A (ja) 2021-12-09
EP3500593A1 (en) 2019-06-26
CA3031995A1 (en) 2018-02-22
PE20190477A1 (es) 2019-04-04
RS62498B1 (sr) 2021-11-30
SG11201900955VA (en) 2019-03-28
TW201806973A (zh) 2018-03-01
MX2019001769A (es) 2019-07-08
US20180051080A1 (en) 2018-02-22
BR112019001922A2 (pt) 2019-07-09
DE102016115246B3 (de) 2017-12-14
MA45976A (fr) 2021-05-19
WO2018033291A1 (en) 2018-02-22
EP3500593B1 (en) 2021-08-25
TWI775768B (zh) 2022-09-01
MX395287B (es) 2025-03-25
US20180319884A1 (en) 2018-11-08
CR20190095A (es) 2019-06-13
AU2021201518A1 (en) 2021-04-01
DE102016115246C5 (de) 2018-12-20
DK3500593T3 (da) 2021-11-01
US10550182B2 (en) 2020-02-04
MA45976B1 (fr) 2021-09-30
AU2017312361B2 (en) 2020-12-10
US10526407B2 (en) 2020-01-07
LT3500593T (lt) 2021-11-25
AU2017312361A1 (en) 2019-02-28
CN109563149A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
JP6964351B2 (ja) 新規ｔ細胞受容体およびそれを用いた免疫療法
US10725044B2 (en) T cell receptors and immune therapy using the same
EP3600409B1 (en) T cell receptors and immune therapy using the same against prame positive cancers
TWI735765B (zh) T細胞受體及其針對prame陽性癌症的免疫治療
US11939376B2 (en) T cell receptors and immune therapy using the same
TWI736719B (zh) 新型t 細胞受體及其免疫治療應用
JP2020529830A (ja) 新規ｔ細胞受容体およびそれを用いた免疫療法
JP2021501589A (ja) 新規操作ｔ細胞受容体およびそれを使用した免疫療法
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
HK40071461A (en) T cell receptors and immune therapy using the same
HK40010473B (en) T cell receptors and immune therapy using the same
HK40020731B (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731A (en) T cell receptors and immune therapy using the same against prame positive cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210804

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210823

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211012

R150 Certificate of patent or registration of utility model

Ref document number: 6964351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250